The FDA has approved Eli Lilly's (NYSE: LLY) new Alzheimer's treatment, Kisunla, for early-stage patients, marking it as the second therapy in the U.S. to slow Alzheimer's progression. Priced at $32,000 annually, Kisunla is expected to achieve over $5 billion in peak sales.
